Maastricht 2017 Meeting Highlights Registration Programme Overview Exhibition Virtual Exhibition Hotels Satellite Meetings Visa Letter Application Star Alliance Travel Discount

10 - 12 February 2017, MECC Maastricht,The Netherlands.

This Meeting has been awarded 15 CME credits.

PresbyLASIK-isovision bilateral treatment

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Refractive
Session Date/Time: Friday 10/02/2017 | 10:30-12:30
Paper Time: 11:36
Venue: Brussels Room 0.4

First Author: M.Rau GERMANY
Co Author(s): F. Hehn                 

Abstract Details


To evaluate a new Presbylasik, Presbylasek approach, correcting distance vision in both eyes equal to emmetropia with an additional treatment of presbyopia with a controlled amount of Q asphericity factor


Refractive centre Prague ,CZ Centre de la vision 54500 Vandoeuvre, France


65 patients with 130 eyes were included . Isovision-technology software was used based on refraction, Addition for near, K reading and Q asphericity .It is a two steps treatment in a single procedure . WFO (wavefront optimized treatment) to achieve the emetropia, the second one is an F-CAT ( Q Factor customized ablation treatment) for near vision. We examined the UCVA for distance and near , cornea topography K reading and Q asphericity,emetropia, and F-CAT ( Q Factor customized ablation treatment) for near vision. . The follow up was 1, 3, 6 months.


Three months postop. 80% of patients achieved binocular UCDVA 16/20 or better and 85% binocular UCNVA p3 or better. 85% of patients were able to read without glasses after one and three months after the surgery. 20 % of patients have a decrease of UCVA for distance after 1 month in average of two lines, after 3 months of 1.75 lines, after 6 months of 0,89 line ,Only 6 % of patients needed glasses for small print occasionally after 6 months.


The ISOVISION Presbylasik is an effective, safe method in the treatment of presbyopia, without altering the stereovision. Further studies are necessary to confirm these preliminary results

Financial Disclosure:


Back to previous